Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Dynavax Technologies Corporation
DVAXCurrent price
11.17 USD
+0.2 USD (+1.82%)
Last closed
10.97 USD
Company
www.dynavax.com
ISIN
US2681582019
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Capitalization
1 424 448 256 USD
Yield for 12 month
-17.69 %
1Y
3Y
5Y
10Y
15Y
DVAX
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California. Address: 2100 Powell Street, EmeryVille, CA, United States, 94608
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
24.5 USDP/E ratio
83.6154Dividend Yield
–Current Year
+232 284 000 USD
Last Year
+722 683 000 USD
Current Quarter
+73 795 000 USD
Last Quarter
+50 790 000 USD
Current Year
+182 117 000 USD
Last Year
+460 530 000 USD
Current Quarter
+61 810 000 USD
Last Quarter
+39 824 000 USD
Key Figures DVAX
1 year
3 years
5 years
10 years
EBITDA
-7 871 000 USD
Operating Margin TTM
PE Ratio
83.6154
Return On Assets TTM
-0.79 %
PEG Ratio
–
Return On Equity TTM
2.82 %
Wall Street Target Price
24.5 USD
Revenue TTM
249 694 000 USD
Book Value
4.91 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
22.5 %
Dividend Yield
–
Gross Profit TTM
448 218 000 USD
Earnings per share
0.13 USD
Diluted Eps TTM
0.13 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
207.2 %
Profit Margin
6.88 %
Dividend Analytics DVAX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History DVAX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:10
Payout Ratio
–
Last Split Date
10.11.2014
Dividend Date
–
Stock Valuation DVAX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
83.6154
Forward PE
55.2486
Enterprise Value Revenue
3.8469
Price Sales TTM
5.7048
Enterprise Value EBITDA
29.0531
Price Book MRQ
2.2485
Financials DVAX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators DVAX
For 52 weeks
9.74 USD
15.15 USD
50 Day MA
11.02 USD
Shares Short Prior Month
17 892 489
200 Day MA
12.2 USD
Short Ratio
8.54
Shares Short
18 925 087
Short Percent
17.64 %
BeatStart